365 related articles for article (PubMed ID: 36238195)
21. Bruton's tyrosine kinase inhibition-An emerging therapeutic strategy in immune-mediated dermatological conditions.
Mendes-Bastos P; Brasileiro A; Kolkhir P; Frischbutter S; Scheffel J; Moñino-Romero S; Maurer M
Allergy; 2022 Aug; 77(8):2355-2366. PubMed ID: 35175630
[TBL] [Abstract][Full Text] [Related]
22. Bruton's Tyrosine Kinase Inhibitors for Multiple Sclerosis Treatment: A New Frontier.
Greenberg BM
Neurol Clin; 2024 Feb; 42(1):155-163. PubMed ID: 37980113
[TBL] [Abstract][Full Text] [Related]
23. Bruton's tyrosine kinase-bearing B cells and microglia in neuromyelitis optica spectrum disorder.
Liu Y; Huang Z; Zhang TX; Han B; Yang G; Jia D; Yang L; Liu Q; Lau AYL; Paul F; Verkhratsky A; Shi FD; Zhang C
J Neuroinflammation; 2023 Dec; 20(1):309. PubMed ID: 38129902
[TBL] [Abstract][Full Text] [Related]
24. Bruton's tyrosine kinase inhibitors in the treatment of multiple sclerosis.
Shulga O; Chabanova A; Kotsiuba O
Postep Psychiatr Neurol; 2023 Mar; 32(1):23-30. PubMed ID: 37287740
[TBL] [Abstract][Full Text] [Related]
25. Next-generation Bruton's Tyrosine Kinase (BTK) Inhibitors Potentially Targeting BTK C481S Mutation- Recent Developments and Perspectives.
Das D; Wang J; Hong J
Curr Top Med Chem; 2022; 22(20):1674-1691. PubMed ID: 35927919
[TBL] [Abstract][Full Text] [Related]
26. Bruton's Tyrosine Kinase Inhibitors in Multiple Sclerosis: Pioneering the Path Towards Treatment of Progression?
Geladaris A; Torke S; Weber MS
CNS Drugs; 2022 Oct; 36(10):1019-1030. PubMed ID: 36178589
[TBL] [Abstract][Full Text] [Related]
27. Remibrutinib (LOU064) inhibits neuroinflammation driven by B cells and myeloid cells in preclinical models of multiple sclerosis.
Nuesslein-Hildesheim B; Ferrero E; Schmid C; Huck C; Smith P; Tisserand S; Rubert J; Bornancin F; Eichlisberger D; Cenni B
J Neuroinflammation; 2023 Aug; 20(1):194. PubMed ID: 37633912
[TBL] [Abstract][Full Text] [Related]
28. Bruton's tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018).
Feng Y; Duan W; Cu X; Liang C; Xin M
Expert Opin Ther Pat; 2019 Apr; 29(4):217-241. PubMed ID: 30888232
[TBL] [Abstract][Full Text] [Related]
29. BTK inhibition limits B-cell-T-cell interaction through modulation of B-cell metabolism: implications for multiple sclerosis therapy.
Li R; Tang H; Burns JC; Hopkins BT; Le Coz C; Zhang B; de Barcelos IP; Romberg N; Goldstein AC; Banwell BL; Luning Prak ET; Mingueneau M; Bar-Or A
Acta Neuropathol; 2022 Apr; 143(4):505-521. PubMed ID: 35303161
[TBL] [Abstract][Full Text] [Related]
30. Bruton's Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis.
Garg N; Padron EJ; Rammohan KW; Goodman CF
J Clin Med; 2022 Oct; 11(20):. PubMed ID: 36294458
[TBL] [Abstract][Full Text] [Related]
31. Clinical Research Progress of BTK Inhibitors in the Treatment of Autoimmune Diseases.
Lin P; Zhang D; Lin J
Curr Top Med Chem; 2023; 23(28):2609-2620. PubMed ID: 37861005
[TBL] [Abstract][Full Text] [Related]
32. Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib.
Ran F; Liu Y; Wang C; Xu Z; Zhang Y; Liu Y; Zhao G; Ling Y
Eur J Med Chem; 2022 Feb; 229():114009. PubMed ID: 34839996
[TBL] [Abstract][Full Text] [Related]
33. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
Front Immunol; 2021; 12():766272. PubMed ID: 34912339
[TBL] [Abstract][Full Text] [Related]
34. Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies.
da Cunha-Bang C; Niemann CU
Drugs; 2018 Nov; 78(16):1653-1663. PubMed ID: 30390220
[TBL] [Abstract][Full Text] [Related]
35. An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia.
Geethakumari PR; Awan F
Expert Rev Hematol; 2020 Oct; 13(10):1039-1046. PubMed ID: 32869675
[TBL] [Abstract][Full Text] [Related]
36. Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis.
Whang JA; Chang BY
Drug Discov Today; 2014 Aug; 19(8):1200-4. PubMed ID: 24721226
[TBL] [Abstract][Full Text] [Related]
37. New roles for B cell receptor associated kinases: when the B cell is not the target.
Nguyen PH; Niesen E; Hallek M
Leukemia; 2019 Mar; 33(3):576-587. PubMed ID: 30700840
[TBL] [Abstract][Full Text] [Related]
38. BTK inhibition limits microglia-perpetuated CNS inflammation and promotes myelin repair.
Geladaris A; Torke S; Saberi D; Alankus YB; Streit F; Zechel S; Stadelmann-Nessler C; Fischer A; Boschert U; Häusler D; Weber MS
Acta Neuropathol; 2024 Apr; 147(1):75. PubMed ID: 38656399
[TBL] [Abstract][Full Text] [Related]
39. [
Skaddan MB; Wooten DW; Wilcox KC; Voorbach MJ; Reuter DR; Jia ZJ; Foster-Duke KD; Hickson JA; Vaidyanathan S; Reed AD; Tovcimak AE; Guo Q; Comley RA; Lee L; Finnema SJ; Mudd SR
Mol Imaging Biol; 2022 Oct; 24(5):830-841. PubMed ID: 35482146
[TBL] [Abstract][Full Text] [Related]
40. Bruton's tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives.
Seiler T; Dreyling M
Expert Opin Investig Drugs; 2017 Aug; 26(8):909-915. PubMed ID: 28661188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]